• melphalan
• mieloma multiplo
• multiple myeloma
• prednisone
• velcade

In the clinic, I am following approximately 100 patients suffering from Multiple Myeloma (MM), treated with a single dose capsule daily containing (50- 100 mg) of the drug. Thalidomide has shown its efficacy in multiple myeloma, particularly in combination with cortisone. Currently it is used in combination with Melphalan and Prednisone (MPT) as first-line therapy or in combination with Dexamethasone (Dex-Tal) in relapsing patients. Bortezomib (Velcade®) is a very active drug in patients with multiple myeloma. It has been used in experimental protocols in various stages of the disease (first-line therapy or relapse). Many studies have shown a clear superiority of Bortezomib in combination with high-dose Dexamethasone or other drugs (Thalidomide, Doxorubicin, Cyclophosphamide), compared to conventional therapy.